Another possible target for MRD monitoring is DNMT3A, found in 15–25% of AML patients, particularly in CN AML patients.34,35 The presence of DNMT3A mutations is an independent determinant of dismal prognosis both in the overall population and high-risk category (FLT3-ITD, age older than 60 years).34 To explore the utility of DNMT3A mutations as biomarkers for MRD in AML, Pløen et al.36 developed assays for sensitive detection of recurrent mutations affecting residue R882. Here, FLT3 is linked to acute myeloid leukemia.